Trial Profile

A Phase Ib, Open-Label, Pharmacokinetic Drug Interaction Study of the Hedgehog Pathway Inhibitor GDC-0449 in Combination With Rosiglitazone or Combined Oral Contraceptive in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vismodegib (Primary) ; Ethinylestradiol; Norethisterone; Rosiglitazone
Indications Ovarian cancer; Prostate cancer; Solid tumours
Focus Pharmacokinetics
Sponsors Genentech

29 Nov 2012 New source identified and integtrated: (M.D. Anderson Cancer Center: 2010-0472).
25 Aug 2011 Status changed from recruiting to active, no longer recruiting.
23 Nov 2010 Status changed from not yet recruiting to recruiting, according to the Barbara Ann Karmanos Cancer Institute.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com